Browse the evidence

Structured calorie-restricted diets (800-1,800 kcal) can induce diabetes remission in obese Korean adults with early-onset Type 2 Diabetes, with remission rates up to 75%.

If you have recently been diagnosed with Type 2 Diabetes and are obese, a structured diet starting at 800 calories and moving to 1,200-1,800 calories can potentially put your diabetes into remission, especially if you stop other medications under doctor supervision.

A 12-month digital weight management program integrating tirzepatide with behavioral coaching achieves clinically meaningful weight loss (mean 22.7%) and significant improvements in binge eating and depressive symptoms.

If you have obesity and are considering medication, a structured program that combines tirzepatide with digital coaching and support can lead to significant weight loss (over 22% on average) and improvements in mental health and binge eating. Expect some initial side effects like nausea, but these often subside, and clinical support is available to help you manage them.

Both volumetric dieting (energy density ≤ 1.5 kcal/g) and time-restricted eating (8-hour window) produce equivalent reductions in body weight and fat mass while preserving lean body mass in middle-aged, physically active adults over 12 weeks.

If you want to lose fat and keep muscle without changing your exercise routine, you can choose either to eat lower-energy-density foods (more volume, fewer calories per gram) or to eat all your calories within an 8-hour window. Both methods worked equally well in this study. Choose the one you can stick to consistently, as adherence was higher for the time-restricted eating group.

Combining 16:8 TRE with exercise significantly reduces triglycerides and LDL cholesterol compared to exercise alone, with greater LDL-C reductions observed in men.

If you exercise regularly, adding a 16:8 time-restricted eating schedule may lead to small but significant improvements in triglycerides and LDL cholesterol (bad cholesterol) compared to exercising without dietary timing restrictions. Men may see greater improvements in LDL-C. These benefits are modest and should be viewed as part of a broader cardiometabolic risk-reduction plan.

Adopting a Mediterranean diet and maintaining adequate protein intake (1.1–1.2 g/kg/day) are essential public health strategies to prevent chronic diseases, sarcopenia, and functional decline in older adults.

To age healthily, prioritize a Mediterranean-style diet rich in plants, fish, and olive oil, and ensure you are eating enough protein—specifically 1.1 to 1.2 grams per kilogram of your body weight daily. This higher protein target is crucial for preventing muscle loss (sarcopenia) and maintaining your ability to live independently. Combine this with regular physical activity, including resistance and balance exercises, to support your physical and cognitive health.

Regular physical activity, including resistance, aerobic, and balance exercises, reduces the risk of chronic diseases, cognitive decline, and functional impairment in older adults.

Engage in regular physical activity tailored to your abilities. Include resistance training to build muscle, aerobic exercise for heart health, and balance activities to prevent falls. Even moderate activity like walking can significantly reduce the risk of dementia and chronic diseases, improving your quality of life.

Tirzepatide is the only obesity management medication shown to significantly reduce the Apnea-Hypopnea Index (AHI) and achieve remission of Obstructive Sleep Apnea Syndrome (OSAS) in patients with obesity.

If you have obesity and sleep apnea, Tirzepatide has been shown to significantly reduce the severity of your sleep apnea (AHI) and can lead to remission of the condition. This is a unique benefit not clearly demonstrated by other weight loss drugs in this review.

Pancreatic lipase inhibitors, specifically Orlistat, reduce obesity by preventing the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides, thereby reducing caloric intake from fat.

Orlistat works by physically blocking your body from absorbing about 25% of the fat you eat. This leads to weight loss, but it comes with a high likelihood of gastrointestinal side effects like oily stools and gas. To minimize these side effects, you must strictly limit the amount of fat in your diet, particularly with each dose. It is a tool for weight management, not a free pass to eat high-fat foods.

Patients using GLP-1 receptor agonists (GLP-1RA) for weight loss consistently fail to meet Dietary Reference Intakes (DRI) for key micronutrients (fiber, calcium, iron, magnesium, potassium, choline, vitamins A, C, D, E, K) and MyPlate food group servings (fruit, vegetables, grains, dairy).

If you are taking a GLP-1RA, your reduced appetite likely means you are not getting enough fiber, calcium, magnesium, and vitamins. You must actively track your food intake to ensure you are hitting micronutrient goals, as you cannot rely on feeling full. Focus on nutrient-dense foods and consider supplementation if dietary intake remains low, as standard portion sizes are likely insufficient.

GLP-1RA users often underconsume protein relative to their increased needs for preserving lean mass during rapid weight loss, despite protein percentage of calories being within the Acceptable Macronutrient Distribution Range (AMDR).

Even if your protein percentage looks fine, you are likely not eating enough grams of protein to protect your muscles while losing weight rapidly on GLP-1RA. Aim for 1.2-2.0 g of protein per kg of body weight daily. Prioritize lean protein sources in every small meal.

Myostatin-activin pathway inhibitors (MAPi), specifically bimagrumab, can reduce fat mass while preserving or increasing lean mass, offering a potential solution to the lean mass loss associated with GLP-1 agonists.

If you are concerned about losing muscle on weight loss drugs, ask your doctor about Myostatin-Activin Pathway Inhibitors (MAPi) like bimagrumab. In studies, this drug helped patients lose fat while actually gaining muscle. It is currently being studied in combination with GLP-1 drugs.

Combining GLP-1 receptor agonists with other Nutrient Stimulated Hormones (NuSH) like glucagon or amylin, or using dual/triple agonists like tirzepatide, may result in less lean mass loss compared to single-agonist GLP-1 treatments.

If you are on semaglutide and worried about muscle loss, ask your doctor if tirzepatide (a dual GLP-1/GIP drug) might be a better option for you, as it appears to spare more muscle. Newer triple-agonist drugs are also in development.

GLP-1 receptor agonists (GLP-1 RA) are associated with significant weight regain after discontinuation, whereas non-GLP-1 related treatments did not show statistically significant regain in this meta-analysis.

If you are on a GLP-1 medication (like semaglutide or liraglutide), stopping it is likely to cause significant weight regain due to the loss of appetite suppression. Other drugs may not show this same statistical pattern of regain in this analysis, but individual responses vary.

Low-carbohydrate diets (LCDs) and calorie restriction can improve cognitive function and combat age-related cognitive decline through mechanisms involving reduced oxidative stress, anti-inflammatory responses, and enhanced neurogenesis.

Limit carbohydrates to less than 20% of your calories, focusing on fats and proteins from meat, poultry, fish, eggs, cheese, nuts, and seeds. This approach may help combat age-related cognitive decline, especially if you have obesity or type 2 diabetes. Monitor your lipid profile as high fat intake can raise LDL.

Persistent, intrusive, and dysphoric thoughts about food (food noise) are a distinct psychological construct that can be significantly reduced by GLP-1 receptor agonists, leading to improved quality of life and weight management outcomes.

If you experience constant, intrusive, and unpleasant thoughts about food that interfere with your life, this may be 'food noise,' a distinct psychological construct. GLP-1 receptor agonists (like semaglutide) have been shown to significantly reduce this noise, leading to better weight loss outcomes and improved quality of life. This is not a failure of willpower but a treatable condition.

Post-exercise protein ingestion stimulates myofibrillar muscle protein synthesis (MPS) but has little to no effect on mitochondrial MPS rates during recovery from endurance exercise.

Eat protein after your endurance workout to help repair muscle fibers. However, don't expect it to directly boost your mitochondrial energy production; that is driven more by the exercise itself.

Diabetes screening should begin at age 35 for all adults, or age 19 for those with specific risk factors, utilizing FPG, HbA1c, or OGTT.

If you are 35 or older, get your blood sugar checked now, even if you feel fine. If you are younger than 35 but have risk factors like abdominal obesity, start screening at 19. Early detection prevents long-term damage.

Combined blockade of GDF8 (myostatin) and Activin A using monoclonal antibodies significantly increases lean muscle mass and decreases fat mass in postmenopausal women, with effects reversing to baseline upon cessation of treatment.

For postmenopausal women seeking to increase muscle mass, blocking both myostatin and activin A via antibody therapy produces significant muscle growth and fat loss. However, this effect is not permanent; stopping treatment leads to a return to baseline muscle size within about 6 months. The treatment requires regular IV infusions and carries mild side effects like muscle spasms. It is not a lifestyle intervention but a medical therapy requiring clinical supervision.

Intensive Weight Management Programmes (IWMPs) utilizing Total Diet Replacement (TDR) achieve substantial, sustained weight loss (5-15%) and metabolic improvements in populations with obesity and type 2 diabetes, though specific evidence for women with PCOS is currently insufficient.

For women with PCOS, standard diet and exercise advice often fails to produce lasting metabolic benefits. Intensive programs using meal replacements (TDR) for a few months, followed by a structured return to food, can produce significant weight loss (5-15%) and improve metabolic health. However, because specific studies on PCOS are lacking, this approach should be considered promising but unproven for this specific group, requiring careful monitoring.

Tirzepatide demonstrates superior efficacy compared to Semaglutide in reducing HbA1c levels, but shows no clear superiority in weight loss or FBS reduction.

If your current Semaglutide treatment is not lowering your HbA1c enough, switching to Tirzepatide may provide better blood sugar control. However, do not expect significantly more weight loss from this switch, as both drugs appear to offer similar weight reduction benefits in this analysis.

Switching from Liraglutide to Semaglutide results in significant additional weight loss and FBS reduction, but does not significantly impact HbA1c levels.

If you are currently on Liraglutide and struggling with weight or fasting blood sugar, switching to Semaglutide may help you lose more weight and lower your FBS. However, this switch is unlikely to significantly improve your HbA1c levels.

Moderate consumption of dairy products, particularly fermented dairy like yogurt, is associated with reduced cardiovascular risk and lower long-term weight gain, contrary to historical concerns about saturated fat.

You can include moderate amounts of dairy in your diet, especially fermented options like yogurt and cheese. They are linked to lower cardiovascular risk and weight gain. Avoid very high intake (>1000g/day).

GLP-1 receptor agonists facilitate significant weight loss and metabolic improvement in non-pregnant women, but current evidence does not demonstrate that pre-pregnancy use improves pregnancy outcomes and may be associated with increased gestational weight gain.

GLP-1 drugs like Semaglutide cause significant weight loss in women with obesity. However, because there is no proof they improve pregnancy outcomes and animal studies suggest potential fetal growth restriction (likely due to maternal weight loss/nutrition), they are not currently recommended for improving pregnancy success. Women using these drugs should use effective contraception and stop the medication at least 6 weeks before trying to conceive, as advised by current guidelines.

Higher Dietary Inflammatory Index (DII) scores are independently associated with an increased risk of Coronary Heart Disease (CHD), with a 1-unit increase in DII corresponding to an odds ratio of 1.049 for CHD after adjusting for confounders.

Focus on reducing pro-inflammatory foods and increasing anti-inflammatory ones, specifically paying attention to carbohydrate quality, ensuring adequate Vitamin C and Iron intake. While you don't need to calculate a complex index, these specific nutrients appear to drive the inflammatory response linked to heart disease risk.